Perea Sofia, López-Ribot José L, Wickes Brian L, Kirkpatrick William R, Dib Olga P, Bachmann Stefano P, Keller Suzanne M, Martinez Marcos, Patterson Thomas F
Department of Medicine, Division of Infectious Diseases, The University of Texas Health Science Center at San Antonio, 78245, USA.
Antimicrob Agents Chemother. 2002 Jun;46(6):1695-703. doi: 10.1128/AAC.46.6.1695-1703.2002.
Candida dubliniensis is a newly identified species of Candida that is phenotypically similar to but genetically distinct from C. albicans. This organism has been recovered with increasing frequency from the oral cavities of human immunodeficiency virus (HIV)-infected and AIDS patients and has been implicated as a causative agent of oral candidiasis and systemic disease. In the present study we characterized the molecular mechanisms of resistance to fluconazole (FLC) in C. dubliniensis clinical isolates from two different HIV-infected patients with oropharyngeal candidiasis. Isolates were identified to the species level by phenotypic and genotypic tests. DNA-typing techniques were used to assess strain identity. Antifungal susceptibility testing was performed by NCCLS techniques. Northern blotting analysis was used to monitor the expression of genes encoding lanosterol demethylase (ERG11) and efflux transporters (CDR and MDR1) in matched sets of C. dubliniensis-susceptible and -resistant isolates by using probes generated from their homologous C. albicans sequences. In addition, ERG11 genes were amplified by PCR, and their nucleotide sequences were determined in order to detect point mutations with a possible effect in the affinity for azoles. Decreasing susceptibilities to FLC were detected in C. dubliniensis isolates recovered from both patients during the course of treatment. FLC-resistant C. dubliniensis isolates from one patient demonstrated combined upregulation of the MDR1, CDR1, and ERG11 genes. Among the isolates from the second patient, all isolates showing decreased susceptibility to FLC demonstrated upregulation of MDR1, whereas the levels of mRNA for the ERG11 genes remained constant and the expression of CDR genes was negligible. Fourteen point mutations were found in the ERG11 genes of the isolates with decreased susceptibility to FLC. These data demonstrate that the development of azole resistance in C. dublinensis clinical isolates from HIV-infected patients treated with FLC is mediated by multiple molecular mechanisms of resistance, similar to the observations found in the case of C. albicans.
都柏林念珠菌是一种新发现的念珠菌属菌种,其表型与白色念珠菌相似,但基因上有所不同。这种微生物在人类免疫缺陷病毒(HIV)感染患者和艾滋病患者口腔中被分离出的频率越来越高,并被认为是口腔念珠菌病和全身性疾病的病原体。在本研究中,我们对来自两名患有口咽念珠菌病的不同HIV感染患者的都柏林念珠菌临床分离株对氟康唑(FLC)的耐药分子机制进行了表征。通过表型和基因型测试将分离株鉴定到种水平。使用DNA分型技术评估菌株同一性。采用美国国家临床实验室标准委员会(NCCLS)技术进行抗真菌药敏试验。通过使用从其同源白色念珠菌序列产生的探针,采用Northern印迹分析监测都柏林念珠菌敏感和耐药分离株配对组中编码羊毛甾醇脱甲基酶(ERG11)和外排转运蛋白(CDR和MDR1)的基因表达。此外,通过PCR扩增ERG11基因,并测定其核苷酸序列,以检测可能影响对唑类亲和力的点突变。在治疗过程中,从两名患者中分离出的都柏林念珠菌分离株对FLC的敏感性均降低。来自一名患者的耐FLC都柏林念珠菌分离株显示MDR1、CDR1和ERG11基因联合上调。在来自第二名患者的分离株中,所有对FLC敏感性降低的分离株均显示MDR1上调,而ERG11基因的mRNA水平保持不变,CDR基因的表达可忽略不计。在对FLC敏感性降低的分离株的ERG11基因中发现了14个点突变。这些数据表明,在用FLC治疗的HIV感染患者的都柏林念珠菌临床分离株中,唑类耐药性的产生是由多种耐药分子机制介导的,这与白色念珠菌的情况相似。